Othram

Houston, United States Founded: 2018 • Age: 8 yrs
Genomic services are provided for forensic investigations and research.

About Othram

Othram is a Healthcare company based in Houston (United States) founded in 2018 by David Mittelman. Genomic services are provided for forensic investigations and research. Othram has raised $43.16 million across 7 funding rounds from investors including Illumina and Gigafund. The company has 22 employees. Its chief executive, as recorded, is David Mittelman. Its website othram.com draws about 22 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Other Applications. Its legal entity is Othram Inc. Its competitors include DDC Paternity Tests, Applied DNA Sciences and IntegenX; 1 of its 3 listed competitors has raised funding.

Company details

Othram was founded in 2018 and is based in Houston, United States. Operations focus on the genomics sector, where proprietary biomarkers are utilized to analyze genome profiles for forensic and investigative purposes. DNA is recovered from minimal samples through amplification techniques. Solutions are offered for identifying traits such as ancestry lineage, hair color, height, and genetic relatives by comparing genome sequences.

  • Headquarters Houston, United States
  • Employees 22
  • Founders David Mittelman
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website othram.com
  • Social LinkedIn X
  • Legal Name Othram Inc
Key Metrics
  • Total Equity Funding
    $43.16M (USD)

    in 7 rounds

  • Latest Funding Round
    $10M (USD), Series B

    Sep 2026

  • Investors
    Illumina

    & 1 more

  • Employee Count
    22

Funding Insights of Othram

Othram has successfully raised a total of $43.16M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $43.16M
  • Total Rounds 7
  • Last Round Series B β€” $10M
  • First Round $4M

    (Mar 2019)

  • Investors Count 2

All 7 funding rounds of Othram with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2026$10MDebt – Conventional––
–
Sep 2026$10MSeries B––
–
Feb 2024$6.56MSeries B––
–
Sep 2021$18MSeries B–Gigafund
–
May 2020$4.6MSeries A––
–
Apr 2019$10,000Grant––
Mar 2019$4MSeries A––
–
Valuation history

2 investors in total: 2 institutional.

Investors in Othram

Othram has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina and Gigafund.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm investing in multiple sectors
gigafund.comAustin, United States
Developer of technologies for analysis of genetic variation and function
1993illumina.comSan Diego, United States
Premium access

Investor details for Othram

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Othram

7 people are tracked at Othram (6 in leadership, 1 in team); the tracked headcount is 22.

NameRoleGroup
David Mittelman
Co-Founder & CEOLeadership
Kristen Mittelman
Chief Business Development OfficerLeadership
Adrian Lopez
Director of FinanceLeadership
Brendan Belair
Chief Strategy OfficerLeadership
Colby L.
Chief Of StaffLeadership
Lee Baker
Director Of EngineeringLeadership
Patrick Kinder
General CounselTeam
Premium access

Complete people profiles for Othram

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Othram

3 dated milestones of Othram across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Othram is founded.
  2. Funding First funding round of $4.0M.
  3. Funding Latest funding round, Series B, of $10.0M.

Competitors of Othram

Othram has 3 listed competitors in our database, 1 of them funded. They include DDC Paternity Tests, Applied DNA Sciences and IntegenX.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
dnacenter.com1995Fairfield, United States
DNA tests and personalized diagnostics are provided for various specialties.
adnas.com1983Stony Brook, United States55
Botanical-DNA-based security and authentication solutions are developed.
integenx.com2006Pleasanton, United States$92.06M78
Instruments for rapid human DNA identification are developed.
Premium access

Detailed competitors of Othram

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Othram

The website of Othram (othram.com) receives about 22.3K visits a month.

  • Monthly visits
    22.3K

    ▲ 128% vs previous month

Similar websites

Websites whose visitors overlap most with Othram. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
rcfl.gov
rcfl.gov
100%
#3,842,205–

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Othram (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Othram

Premium access

Complete news archive for Othram

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Othram

Othram was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Othram is headquartered in Houston, United States. It is registered at Houston, Texas, United States.

David Mittelman is the CEO of Othram, as recorded in our data. They have also founded this company.

Othram is a funded company, having raised a total of $43.16M across 7 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Mar 2019.

Othram has 22 employees.

Othram was founded in 2018 and is based in Houston, United States. Operations focus on the genomics sector, where proprietary biomarkers are utilized to analyze genome profiles for forensic and investigative purposes. DNA is recovered from minimal samples through amplification techniques. Solutions are offered for identifying traits such as ancestry lineage, hair color, height, and genetic relatives by comparing genome sequences.

Othram's top competitors include DDC Paternity Tests, Applied DNA Sciences and IntegenX.

Othram has 2 investors. Key investors include Illumina, and Gigafund.

Othram operates through Othram Inc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available